The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression
Dongxiao Lv, Ruibin Wang, Xingwen Wang, Hong FengJournal of Cancer Research and Therapeutics 2022 18(2):587-589 In non-small cell lung cancer (NSCLC), about 15% of epidermal growth factor receptor (EGFR) mutations are rare. Herein, we report a 39-year-old male with stage IV NSCLC with a rare EGFR M277E mutation and high PD-L1 expression. The patient first underwent gamma-knife treatment for brain metastasis; then, he was started on 40 mg afatinib daily in combination with two cycles of chemotherapy. The clinical effect was stable disease (SD), so the patient underwent intensity-modulated radiation therapy guide...
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Dongxiao Lv Ruibin Wang Xingwen Wang Hong Feng Source Type: research

Association of microRNA polymorphisms with gastric cancer risk in the North Chinese Han population
Conclusions: The present study showed no association of the investigated miRNA SNPs with the risk of GC in the north Chinese population. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Qian Xin Shan Shan E Ding Mingxin Jin Bei Li Jiangxia Li Qiji Liu Cuihua Yi Jisheng Li Source Type: research

Effectiveness and safety of camrelizumab combined with chemotherapy in nonsquamous nonsmall cell lung cancer as the second-line therapy: A retrospective analysis
Conclusions: Camrelizumab combined with chemotherapy was an effective regimen with manageable toxicity in treating nonsquamous NSCLC as the second-line therapy. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Wei Huang Qinyuan Zhang Liangshan Da Yuanyuan Shen Fuxing Xiong Congjun Zhang Source Type: research

Significance of vasohibin 1 in cancer patients: A systematic review and meta analysis
This study analyzed the role of vasohibin-1 (VASH1) in human cancer outcomes. Relevant original studies on VASH1 expression in cancers were searched from PubMed, ClinicalKey, and Cochrane Library databases. A meta-analysis was performed to evaluate the role of VASH1 in clinicopathological characteristics and overall survival (OS) of patients with tumors. Statistical analysis was performed using the RevMan v. 5.3 software. Our meta-analysis results showed that patients with high VASH1 expression experienced a significantly poor prognosis with a hazard ratio (HR) of 1.69 (95% confidence interval [CI], 1.16&...
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Shuai Liu Bing Han Meili Sun Jingnan Wang Yuping Sun Yunshan Wang Source Type: research

Influencing factors related to transcatheter arterial chemoembolization for hepatocellular carcinoma patients achieved tumor response
Conclusions: This study suggests that TACE combined with ablation on patients with complete tumor capsules may have a better prognosis in tumor response and OS; additionally, liver dysfunction and nausea and vomiting were the independent predictors of tumor response. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Hongyan Shao Juan Deng Luping Xie Qiwen Zheng Bihui Zou Jun Deng Tianqi Zhang Jingjing He Source Type: research

Elevated & #946;-catenin and C-myc promote malignancy, relapse, and indicate poor prognosis in patients with relapsed glioma
Conclusions: Elevated β-catenin and C-myc promote malignancy, relapse, and indicate poor prognosis in patients with relapsed glioma. The elevated levels of β-catenin and c-myc in relapsed glioma were not affected by radiation therapy. The results of this study may provide a new therapeutic target for patients with relapsed glioma. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Xuejuan Yu Fengxia Xiao Yuzhen Wei Lifeng Miao Wei Zhang Xin Zhang Dexiang Wang Source Type: research

PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy
Conclusion: Using PD-1 inhibitors in a combination treatment may improve PFS and OS, with acceptable toxicities. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Guanli Yang Hongfu Sun Chunyang Zhou Nini Sun Lixia Xu Wei Huang Baosheng Li Source Type: research

Microwave ablation of non-small cell lung cancer tumors changes plasma levels of cytokines IL-2 and IFN- & #947
Conclusion: MWA of NSCLC tumors influenced the plasma levels of cytokines IL-2 and IFN-γ. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Hui Xu Xiaojing Tan Yongmei Kong Yahan Huang Zhigang Wei Xin Ye Source Type: research

The efficacy of PD-1 inhibitors in the maintenance treatment of diffuse large B-cell lymphoma: A single-center retrospective analysis
Conclusion: Maintenance treatment with PD-1 inhibitors can improve the 2-year RFS rate of patients with IPI score of ≥3 and non-GCB DLBCL. This prompts the potential advantage of PD-1 inhibitors in DLBCL maintenance treatment. However, longer follow-ups remain needed to obtain more definite data. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Li-ya Wei Jing Xie Yue-qiao Wang Xuan-yong Liu Xiao Chen Yi-huizhi Zhang Qiang Wang Zhi Guo Source Type: research

Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-rearrangement non-small-cell lung cancer patients with brain metastases in China
Conclusion: Ceritinib administered at 450 mg QD to ALK-rearrangement NSCLC patients with BM in China exhibited superior ORR and DCR, as well as PFS and event free probability. The estimated 12-month EFP for intracranial lesions improved in patients with prior brain radiotherapy. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Zhixin Qiu Xinhong Xian Chunrong Liu Min Yu Feng Lin Meijuan Huang Ke Wang Source Type: research

Percutaneous microwave ablation under ultrasound guidance for renal cell carcinomas at clinical staging T1 in patients aged 65 years and older: A comparative study
Conclusion: Due to the corresponding clinical outcomes for the treatment of cT1 RCCs in patients aged <65 years and ≥65 years, the US-guided MWA is a safe and effective method and may be suggested as one of the first-line nonsurgical options for identified older patients. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Zhigang Cheng Xiaoling Yu Zhiyu Han Fangyi Liu Jie Yu Jian Yang Danni Ai Ping Liang Source Type: research

Factors contributing to the mortality of elderly patients with colorectal cancer within a year after surgery
Conclusion: Postoperative complications were associated with the early death of elderly CRC patients. CA19-9 levels and ASA grades are independent factors influencing OS and DFS. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Wei Shang Wenguang Yuan Ran Liu Chuanwang Yan Mofan Fu Hui Yang Jingbo Chen Source Type: research

The role of surgery on locoregional treatment of patients with breast cancer newly diagnosed with ipsilateral supraclavicular lymph node metastasis
Conclusion: Radiotherapy may be the primary locoregional treatment approach for patients with breast cancer who present with newly diagnosed ISLNM. Additionally, supraclavicular surgery may be more appropriate for patients with negative ER who received radiotherapy. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Bo-Wen Liu Li-Xuan Chen Ke Ma Jiang-Rui Chi Zheng-Jun Yang Yue Yu Xu-Chen Cao Source Type: research

Golgi phosphoprotein 3 promotes ovarian cancer progression and is associated with cisplatin resistance
Conclusion: This study found that GOLPH3 may promote the migration and invasion of OC cells through PI3K/Akt/mTOR pathway. At the same time, low expression of GOLPH3 increased the sensitivity of OC cells to cisplatin. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Teng Liu Zhen-Wei Jin Ying Li Ge Zhang Xiao-Ying Yang Xiao-Meng Xu Ying-Chun Ma Source Type: research

Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial
Conclusions: Combination therapy of camrelizumab and albumin-bound paclitaxel and carboplatin shows promising efficacy and manageable toxicities in patients with recurrent or metastatic cervical cancer. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Xiaoling Zhang Jinlong Chen Naifu Liu Qian Wang Qian Wu Fufeng Gao Yingchun Sang Ping Wang Source Type: research